I managed to submit my comments to the FDA re COVID-19 vaccines at 15 minutes before the deadline last night.
Here are my edited comments:
Subject line: Adaptive Immunity Vaccines Should NOT be Used Against RNA Pandemic Viruses
Comment Tracking Number: 14x-15pw-qfu9
VRBPAC (FDA) submitted June 27, 2022.
Necessitating Very Careful and Intensive Assessment of Newly Formulated (Omicron new strains) Boosters for Risk versus Benefit Including Symptomatic Infection, Hospitalization, ICU admissions and Death Including ALL-CAUSE MORTALITY (with at least one year of blinded follow-up).
From: Dr. Marian Laderoute, Ph.D. Medical Sciences-Immunology
Care must be taken at the time of vaccination to prevent SARS-CoV-2 transmission which can artificially reduce VE as reported in Ontario, Canada especially for the first dose (see Chung H et al, BMJ August 20, 2021). Therefore, any analysis of VE must include assessment at one week post immunization, 2 weeks, 3 weeks, 4 weeks and 6 weeks (for symptomatic infection, hospitalization, ICU admission, and death {for the latter including COVID-19, NON-COVID-19, and total}.
If you really wanted to help matters, you should require all COVID-19 vaccine assessments to include HERV-K102 particle production, genomic proviral copy number as assessed in NPS, blood and BALF as well as HERV-K102 envelope specific antibody using the methods described previously (Laderoute M et al, AIDS, 2007) given that HERV-K102 has been identified as a candidate correlate of protection against COVID-19 (see attached docs).
Remarkably antibodies to SARS-CoV-2 spike correlate with progression and not protection
and the use of these surrogate markers of protection to validate the efficacy of a COVID-19 vaccine is utter nonsense. May I refer you to pages 26 to 30 of the investigative report where I refute 3 rogue claims published in high profile journals suggesting SARS-COV-2 spike antibodies are protective against COVID-19.
If you have any questions, please do not hesitate to ask (xxxxxxxxx or xxxxxxxx).
I have a background in vaccine safety having served on the Brighton Collaboration Viral Vector Vaccine Safety Working Group under Dr. Robert Chen. I am a global expert in HERV-K102 and immunosenescence (the key risk factor along with vitamin D deficiency for risk of COVID-19 severity) including the prevention and reversion of immunosenescence using nutraceuticals. I discovered HERV-K102 as a replication competent foamy retrovirus unique to humans which plays a key role in protection against enveloped RNA pandemic viruses such as HIV-1 and now against SARS-CoV-2, while the Research Manager of Blood Zoonotics at the Public Health Agency of Canada.
I was also involved in the Health Canada heparin recall response in 2008, and in forcing the 'voluntary withdrawal' of Raptiva (efalizumab) from the Canadian market (2009) based on my post-market pharmacovigilance assessment during 2007. I note that two-three months follow-up in the RCT for Raptiva was in hindsight insufficient to assure its safety and the same goes for any vaccine, especially adaptive immunity vaccines against an enveloped RNA pandemic virus with or without a novel gene-therapy technology.
Did it not occur to you that there is no safe or effective adaptive immunity vaccine against HIV-1 or SARS-CoV-1? Is it any wonder why the COVID-19 adaptive vaccines are neither safe nor effective?
I am also providing some visuals explaining how the HERV-K102 system kills SARS-CoV-2 infected cells, and how the antibody to HERV-K102 envelope may neutralize and clear SAR-CoV-2 viruses.
In other words, trained immunity and not adaptive immunity is the only effective way to immunize to combat RNA pandemic viruses.
Thank you for your work and effort😊Sadly they DO KNOW and they DONT CARE.££££ and control is what matters to the top decision makers.
Your excellent report will be added to all the other reputable doctors reports, Dr R Malone Dr P McCullough, Dr Ryan Cole et al….
The system is corrupt, but Thank You again for trying.